Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
Multiple myeloma is a disease of B-lymphocytes producing malignant plasma cells. Malignant
plasma cells induce osteolytic lesions, which is characteristic for progression of multiple
myeloma. It is the aim of this study to investigate whether zoledronic acid has an influence
on the progression of multiple myeloma.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Calcium Calcium, Dietary Diphosphonates Ergocalciferols Vitamin D Vitamins Zoledronic Acid